Media
News & press release
Dipharma SA confirms the recognition as one of the best companies to work for in Switzerland
Chiasso, Switzerland, November 6th, 2023 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized for the second time as one of the best places to work in Switzerlan...
Sapropterin Dihydrochloride sachets and tablets are now available in the United Kingdom
Chiasso, Switzerland and Reading, England, October 4th, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are delighted to announce the official launch of Sapropterin Dihydrochloride (“Sapropterin”) in the United Kingdom. Sa...
Sapropterin Dipharma is now available in Europe and Switzerland
Chiasso, Switzerland, July 3rd, 2023 – Dipharma SA (“Dipharma”) today announced that its product Sapropterin Dipharma is now available in main European Countries and in Switzerland. Sapropterin Dipharma is available in the form of soluble ta...
Dipharma and LogixX Pharma announce granting of marketing authorisation approval for generic Sapropterin in United Kingdom
Chiasso, Switzerland and Reading, England, June 27, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are pleased to announce that the Medicines and Healthcare Products Regulatory Agency (“MHRA”) has granted Marketing Authorization for ...
Analog Pharma and Dipharma announce US FDA approval of abbreviated new drug application (ANDA) of 20 mg generic nitisinone capsules (temperature stable)
Princeton, NJ and Chiasso, Switzerland, May 31 st , 2023 – Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug applica...
Dipharma SA honored as one of the best companies to work for in Switzerland for 2022
Chiasso, September 15th, 2022 | Dipharma SA, a specialty pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized as one of the best places to work for in Switzerland. During the ass...
Analog Pharma and Dipharma announce US FDA approval of abbreviated new drug application (ANDA) of generic Nitisinone capsules (temperature stable)
Rosemont, PA and Chiasso, Switzerland, June 21st, 2022 – Analog Pharma (“Analog”) and Dipharma S.A. (“Dipharma”) today announced that their nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug ...
Interview with PharmaBoardRoom
Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen the largely unexplored rare diseases generics space and the opportunities in metabolic diseases. Marc-Olivier Geinoz – CEO, Dipharma SA Dipharma SA is a Swiss specialty pha...
Miglustat Dipharma is now available in Switzerland
Chiasso, Switzerland, February 16th, 2021 – Swiss-based Dipharma S.A. (“Dipharma”) today announced that its proprietary product Miglustat Dipharma 100 mg capsules is now available in Switzerland. Miglustat Dipharma, a generic equivalent to Actelio...
Dipharma announces grant of centralised marketing authorization for generic Miglustat in Europe
Chiasso, Switzerland, February 20th, 2019 – – Dipharma S.A. (“Dipharma”) today announced that the European Commission has granted Marketing Authorization of its generic Miglustat. This authorization comes after CHMP positive opinion last December ...